[go: up one dir, main page]

EP1523575A1 - Jeu ordonne d'acides nucleiques constitue de genes selectifs de monocytes-macrophages - Google Patents

Jeu ordonne d'acides nucleiques constitue de genes selectifs de monocytes-macrophages

Info

Publication number
EP1523575A1
EP1523575A1 EP03740060A EP03740060A EP1523575A1 EP 1523575 A1 EP1523575 A1 EP 1523575A1 EP 03740060 A EP03740060 A EP 03740060A EP 03740060 A EP03740060 A EP 03740060A EP 1523575 A1 EP1523575 A1 EP 1523575A1
Authority
EP
European Patent Office
Prior art keywords
genes
mrna
array according
array
xref
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP03740060A
Other languages
German (de)
English (en)
Inventor
Bruno STUHLMÜLLER
Thomas Haeupl
Olaf Kiesslich
Gerd-Rüdiger Burmester
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
OLIGENE GmbH
Original Assignee
OLIGENE GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by OLIGENE GmbH filed Critical OLIGENE GmbH
Publication of EP1523575A1 publication Critical patent/EP1523575A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Definitions

  • the invention relates to an array consisting of oligonucleotide or polynucleotide probes which are immobilized and applied to a solid support.
  • the array is characterized in that sequences of a selection or all of the selective monocyte-macrophage genes mentioned in Tables 1-6 are bound to the surface.
  • This nucleic acid array enables the diagnosis of rheumatoid arthritis, an accompanying analysis of the B, the effectiveness of the treatment, and the monitoring of side effects in anti-tumor necrosis factor (TNF) therapy and thus the selection of those for the respective patient with rheumatoid arthritis most effective therapy.
  • the present invention further relates to a nucleic acid array for the prognosis and for the development of new anti-TNF-directed pharmaceuticals or those pharmaceuticals which intervene in its control loop.
  • the cells of the monocyte / macrophage system are involved in the activation and maintenance of inflammation cascades in the blood and tissue, e.g. B. in the context of rheumatoid arthritis and other chronic inflammatory diseases, but also significantly involved in auto-aggressive diseases.
  • monocytes and macrophages are highly activated, show changes in the number of their surface molecules, come into contact with other cells and secrete certain messenger substances such as TNF-alpha, which ensure that the inflammatory process is maintained.
  • TNF-alpha is a cytokine formed by monocytes / macrophages, lymphocytes and mast cells with an influence on inflammation, sepsis, lipid and protein metabolism, blood formation, angiogenesis, wound healing and immune defense, but which also has cytolytic or cytostatic effects on tumor cells.
  • monocyte macrophages show a characteristic, pathologically altered gene expression pattern with significant differences compared to healthy volunteers.
  • bioinformatic methods known to the person skilled in the art such as, for. B. the significance and cluster analysis can u. a. Identify genes with similar behavior and up- or down-regulated genes from the hybridization patterns of a nucleic acid array.
  • Microarray technology is a miniaturization of analytical methods based on DNA or RNA hybridization in a high-throughput method. At the same time, many thousands of different DNA / DNA (DNA / RNA) interactions can be analyzed within one test batch. mRNA expression profiles are determined using DNA arrays by hybridizing labeled cRNA or cDNA samples. These technologies require a high level of automation and standardization with
  • DNA sequence information (Sequence information, oligonucleotides).
  • the DNA arrays currently used differ in the carrier material (nylon membranes, glass surfaces, noble metal vapor-coated glass surfaces, plastics), the length or the production of the DNA sequences immobilized on the carrier and the labeling technique for a sample to be bound.
  • carrier material nylon membranes, glass surfaces, noble metal vapor-coated glass surfaces, plastics
  • DNA sequences can be punctiform and in a systematic order with a filter
  • RNA can be purified from a clinical or pharmaceutical sample to be investigated and, after transcription, by reverse transcription with the complementary nucleic acid strands on the array, the number of genome-wide ones or one already Preselected number are applied to be hybridized.
  • the sample is labeled using built-in radioactive nucleotides, via biotin-streptavidin interactions, digoxigenin-enzyme enhancements or via direct or indirect built-in fluorescent dyes.
  • the information is read out via the intensity of the radioactivity or the fluorescence at a specific location of the support material and thus allows conclusions to be drawn as to what relative amount of specifically bound DNA or RNA sequence was present in the labeled sample.
  • Switching genes on and off is the basis of all biological processes and also an extremely sensitive response to changing external conditions.
  • RNA With the extraction of RNA from a biological sample, the action of labeled cDNA or RNA on a nucleic acid array (hybridization) and its analysis, a great deal of information about the state of the cells in the biological sample under changed conditions is possible within a very short time ,
  • the technology based on the hybridization of nucleic acids has the advantage of extremely high specificity, sensitivity and relatively easy, fast feasibility.
  • Anti-TNF-directed therapies for rheumatoid arthritis and other chronically inflammatory or auto-aggressive diseases discuss on the one hand a potential development of neoplastic changes up to the formation of tumors, and on the other hand the anti-TNF therapy reduces the immune defense, so that more infections occur in the treated patients , u. a. Tuberculosis.
  • the invention has for its object to provide means for monitoring the effectiveness and side effects of anti-TNF therapy, but also to enable the fine diagnosis of an inflammatory disease and thus the selection of the most effective form of therapy for the respective patient. Another object of the present invention is to monitor the efficacy and side effects of new anti-TNF-directed pharmaceuticals in clinical studies.
  • a new array is created consisting of oligonucleotide or polynucleotide probes which are immobilized on a solid support.
  • the advantage of the invention is a cost saving in the production of the nucleic acid array, because it predominantly contains only genes which are of interest for solving the problem of the invention, which minimizes the effort of data evaluation and thus reduces the cost.
  • the object is achieved by a nucleic acid array, on the surface of which sequences of a selection or all of the selective monocyte-macrophage genes mentioned in Tables 1 to 6 are applied.
  • the sequence can be determined from publicly accessible databases, preferably GeneBank or EMBL.
  • the sequences of the nucleic acids from the array can consist of genes whose expression level is changed by an anti-TNF-effective therapy.
  • nucleic acid array can contain the sequences mentioned in the form of DNA, complementary RNA or chemically modified nucleic acids, preferably PNA (protein nucleic aeid).
  • PNA protein nucleic aeid
  • the genes or gene sequences can be selected genes of rheumatoid arthritis or other chronically inflammatory diseases that are relevant to the disease and side effects, preferably from the monocyte / macrophage cell system. If appropriate, alleles, derivatives and / or splicing variants of the gene or partial gene sequences or 0-ligomer sequences can also be present on the surface of the array. The agreement of the sequences on the array with the corresponding sequences in Table 1-6 should be at least 80% in the protein-coding sections of the mRNA.
  • the support on which the nucleic acids are applied can be any support that is normally used for RNA or DNA arrays.
  • the methods for applying and immobilizing the nucleic acids are state of the art and known to the person skilled in the art.
  • the support can be coated with reactive groups, metal compounds or alloys.
  • the genes or gene sequences can be applied, for example, by spotting methods, immobilization methods or by in-situ synthesis methods of oligomers or in mirror image form in the form of RNA.
  • the array according to the invention can be used, for example, to measure the activation of monocytes / macrophages or the inflammatory activity in the blood or cell tissue in the case of inflammatory diseases, preferably rheumatoid arthritis.
  • the array can e.g. B. for the early detection of the diseases mentioned in genetically pre-stressed patients, even before clinical symptoms manifest.
  • a further area of application is fine diagnosis, preferably the division of patients into subgroups, each of which is different
  • the array can also be used for therapy monitoring, for tracking side effects, for making a prognosis and for identifying new pharmaceutical targets for the diseases mentioned.
  • RNA is isolated using known standard techniques and, if appropriate, used as total RNA or poly A + RNA.
  • Transcriptase can be transcribed into cDNA and labeled with it, eg a fluorescent dye, a radioactive nuclide or an enzyme such as alkaline phosphatase.
  • the RNA can be used directly or unlabeled to hybridize the nucleic acid array. After hybridization of the array with the nucleic acid samples and subsequent washing steps, the binding of the sample to the sequences on the array can be analyzed using any suitable method.
  • fluorescent labeling these are optical methods
  • autoradiography would be used for radioactive labeling and enzymatic labeling for enzyme labeling Detection methods, e.g. B. the conversion of a colorless substrate to a colored product.
  • RNA samples are spotted on coupling carriers and are composed of total RNA or messenger RNA.
  • the RNA serves as a target for the highly significantly expressed genes derived from DNA microarrays according to Table 1-6, which are used as labeled probes for hybridization.
  • the coupling of biotinylated RNA or messenger RNA on streptavidin-coated glass supports (south) is proposed.
  • the RNA After labeling the RNA with biotin derivatives, the RNA is spotted on poly-L-lysine-treated but preferably on streptavidin-coated glass or plastic slides and dried. This prevents degradation of the RNA.
  • covalent coupling of the RNA by binding to reactive support materials is available, which is preferably catalyzed by UV radiation.
  • multiple, simultaneous labeling of different genes, gene units or oligomers with different labeling species e.g. Radioactivity, fluorescein, digoxigenin and enzymatic labels advantageous.
  • enzymatic or radioactive probes are to name markings.
  • Labeled household genes alpha, beta, gamma actin, GAPDH, etc.
  • the detection is preferably carried out in parallel and simultaneously with a maximum of 50 gene probes per batch.
  • this system allows quick diagnostics and offers complex diagnostics, prognostics and therapy control that are individually fast for the patient.
  • the system enables rapid, high-throughput implementation, particularly with pharmacological development strategies.
  • RNA extraction The pure monocyte fractions were taken up in RNA lysis buffer and the RNA was then purified using a commercially available RNA purification kit (Qiagen). The RNA was rewritten into cDNA using established cDNA rewriting methods and then subjected to a further linear amplification step using the “Eberwine protocol” used to produce aRNA (amplified RNA). The quantity and quality of the RNA, cDNA and aRNA were verified by gel electrophoresis, photometric determination and measurements with the Bioanalyzer 2100 (from Agilent).
  • Affymetrix Chip Hybridization For expression analyzes, specific oligonucleotides derived directly from database sequences are used as DNA samples in the Affymetrix system. These are hybridized on the array with targets from fluorescence-labeled reverse transcribed samples in the form of cDNA or with linearly amplified samples in the form of aRNA. The hybridization of the genome-wide Affymetrix array (U-133A) and further processing takes place mechanically under standard conditions according to the manufacturer Affymetrix in a special hybridization and washing device with the special buffers. gene expression patterns are created after hybridization using the ratio of the fluorescence intensities at a specific wavelength. Such high-throughput expression analyzes allow comparisons of the expression amounts of genes simultaneously in healthy and sick persons or comparisons of gene expression before and after drug addition for risk assessment (pharmaceutical / toxicogenomics), for fine diagnosis and for the complexity of diseases.
  • RNA samples from peripheral blood monocytes were used 1.) healthy blood donors, 2.) chronically active patients with rheumatoid arthritis before treatment and 3.) after treatment with TNF-alpha antibodies.
  • the success of the treatment was assessed using parameters that are clear in the laboratory and according to the clinically applicable criteria of the internationally valid parameter tests (ACR criteria).
  • ACR criteria clinically applicable criteria of the internationally valid parameter tests
  • Fig. 1 schematic representation of the cluster analysis
  • the clusters have the following characteristics:
  • CLUSTER-1 The disease-specific gene expression is smaller compared to the healthy, the anti-TNF treatment has no gene regulatory effect.
  • CLUSTER-2 Side effects: Represented by the medicinal effects of the anti-TNF-alpha treatment, there is a reduced expression of the associated genes in the treated patient.
  • CLUSTER-3 The disease-specific gene expression larger compared to the healthy.
  • the anti-TNF-alpha treatment shows a positive effect.
  • CLUSTER-4 The disease-specific gene expression is smaller compared to the healthy.
  • the anti-TNF treatment shows a positive effect.
  • CLUSTER-5 Side effects: Represented by the medicinal effect of the anti-TNF-alpha treatment, there is an increased expression of the associated genes in the treated patient.
  • CLUSTER-6 The disease-specific gene expression is greater compared to the healthy.
  • the anti-TNF-alpha treatment has no gene regulatory effect here.
  • Tables 1-6 list the genes contained in the clusters described above together with the Affymetrix name (left) and their defined GeneBank accession number, including a description.
  • NM__012321.1 / DEF Homo sapiens Ü6 snRNA-associated Sm-like protein (LSM4), mRNA.
  • BIRC1 Homo sapiens baculoviral IAP repeat-containing 1 (BIRC1), mRNA.
  • DEF Homo sapiens DKFZp564J157 protein (DKFZP564J157), mRNA.
  • RAE1 (RNA export 1, S.pombe) homolog / FL gb: ü84720. 1 gb: NM 003610 .1
  • NM_021074.1 / DEF Homo sapiens NADH dehydrogenase (ubiqumone) flavoprotem 2 (24kD) (NDÜFV2), mRNA.
  • GK001 Homo sapiens GK001 protein (GK001), mRNA.
  • GK001 protein / FL gb-AF113221 1 gb-BC001300.1 gb: AF226054.1 gb: NM 020198.1
  • sl / CLONE IMAGE: 455119 /
  • JG Hs.13996 Homo sapiens cDNA: FLJ23260 fis, clone COL05804, highly similar to HSP90911 Human clone 23652 mRNA sequence
  • nbosomal protein S5 RPS5
  • mRNA / GEN RPS5
  • nbosomal protein S5 / FL gb: NM 001009.1 gb: ü! 4970.1
  • NM_004549.1 / DEF Homo sapiens NADH dehydrogenase (ubiqumone) 1, subcomplex unknown, 2 (14.5kD, B14.5b) (NDÜFC2), mRNA.
  • NM_014680.1 / DEF Homo sapiens KIAA0100 gene product (KIAA0100), mRNA.
  • FL gb:BC005008.1 gb: M18216.1 gb: M29541.1 gb: NM 002483.1
  • NM_001725.1 / DEF Homo sapiens bacte ⁇ cidalpermeability-mcreasmg protein (BPI), mRNA.
  • BPI Homo sapiens bacte ⁇ cidalpermeability-mcreasmg protein (BPI), mRNA.
  • IL18RAP Homo sapiens mterleukin 18 receptor accessory protein
  • IL18RAP Homo sapiens mterleukin 18 receptor accessory protein
  • PROD mterleukm 18 receptor accessory protein
  • NM_014673.1 / DEF Homo sapiens KI ⁇ A0103 gene product (KIAA0103), mRNA.
  • / DEF Homo sapiens annosyl (alpha-1, 6-) -glycoprotem beta-l, 2-N-acetylglucosammyltransferase (MGAT2), mRNA.
  • zmc finger protein 146 (ZNF146), mRNA.
  • AF001362.1 / DEF Homo sapiens Jak2 kinase (JAK2) mRNA, complete cds.
  • CGI-29 protein / FL gb: AF132963 .1 gb: NM 015957 .1

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne un jeu ordonné de sondes oligonucléotidiques ou polynucléotidiques qui sont appliquées en étant immobilisées sur un support solide. Ce jeu ordonné se caractérise en ce que sur la surface sont liées des séquences de gènes de monocytes-macrophages sélectifs ou de tous les gènes de monocytes-macrophages mentionnés dans les tableaux 1-6. Ce jeu ordonné permet le diagnostic de l'arthrite rhumatoïde et d'autres maladies inflammatoires chroniques, une analyse simultanée de l'efficacité du traitement et la surveillance d'effets secondaires lors d'une thérapie anti-facteur de nécrose tumorale (TNF), et ainsi la sélection de la thérapie la plus efficace pour chaque patient souffrant d'arthrite rhumatoïde. La présente invention concerne en outre un jeu ordonné d'acides nucléiques permettant d'établir un pronostic et de développer des produits pharmaceutiques anti-TNF ou des produits pharmaceutiques qui interviennent dans la régulation du TNF.
EP03740060A 2002-07-24 2003-05-28 Jeu ordonne d'acides nucleiques constitue de genes selectifs de monocytes-macrophages Withdrawn EP1523575A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10234524 2002-07-24
DE10234524A DE10234524A1 (de) 2002-07-24 2002-07-24 Nukleinsäurearray
PCT/DE2003/001822 WO2004016809A1 (fr) 2002-07-24 2003-05-28 Jeu ordonne d'acides nucleiques constitue de genes selectifs de monocytes-macrophages

Publications (1)

Publication Number Publication Date
EP1523575A1 true EP1523575A1 (fr) 2005-04-20

Family

ID=30128495

Family Applications (1)

Application Number Title Priority Date Filing Date
EP03740060A Withdrawn EP1523575A1 (fr) 2002-07-24 2003-05-28 Jeu ordonne d'acides nucleiques constitue de genes selectifs de monocytes-macrophages

Country Status (5)

Country Link
US (1) US20060216707A1 (fr)
EP (1) EP1523575A1 (fr)
AU (1) AU2003285285A1 (fr)
DE (1) DE10234524A1 (fr)
WO (1) WO2004016809A1 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040248169A1 (en) * 1999-01-06 2004-12-09 Chondrogene Limited Method for the detection of obesity related gene transcripts in blood
US7235358B2 (en) * 2001-06-08 2007-06-26 Expression Diagnostics, Inc. Methods and compositions for diagnosing and monitoring transplant rejection
US6905827B2 (en) 2001-06-08 2005-06-14 Expression Diagnostics, Inc. Methods and compositions for diagnosing or monitoring auto immune and chronic inflammatory diseases
US7026121B1 (en) 2001-06-08 2006-04-11 Expression Diagnostics, Inc. Methods and compositions for diagnosing and monitoring transplant rejection
US7892745B2 (en) 2003-04-24 2011-02-22 Xdx, Inc. Methods and compositions for diagnosing and monitoring transplant rejection
US7645575B2 (en) * 2004-09-08 2010-01-12 Xdx, Inc. Genes useful for diagnosing and monitoring inflammation related disorders
DE102005050933A1 (de) * 2005-10-21 2007-04-26 Justus-Liebig-Universität Giessen Erfindung betreffend Expressionsprofile zur Vorhersage von septischen Zuständen
EP1795610A1 (fr) * 2005-12-06 2007-06-13 Oligene GmbH Composition des acides nucléiques qui sont spécifiques pour des maladies inflammatoires, particulièrement arthrite rheumatoide
WO2008021431A2 (fr) * 2006-08-14 2008-02-21 Xdx, Inc. Méthodes et compositions permettant de diagnostiquer et de surveiller l'état de rejet de greffe et de troubles immunitaires
US7851144B2 (en) * 2006-08-18 2010-12-14 The University Of Washington Compositions and methods for detecting cancer
EP2102367A2 (fr) 2006-11-09 2009-09-23 XDX, Inc. Procedes pour diagnostiquer et surveiller l'etat d'un lupus erythemateux systemique
EP2679995A1 (fr) * 2007-05-31 2014-01-01 AbbVie Inc. Biomarqueurs prédictifs de la réactivité aux inhibiteurs TNF-alfa dans des troubles auto-immuns
EP2056110A1 (fr) 2007-10-31 2009-05-06 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Biomarqueur pour prédire une réponse à un traitement par un anti-TNF-alpha
WO2012016030A2 (fr) * 2010-07-28 2012-02-02 University Of Medicine And Dentistry Of New Jersey Détection d'une inflammation

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6582908B2 (en) * 1990-12-06 2003-06-24 Affymetrix, Inc. Oligonucleotides
JP2000512744A (ja) * 1996-05-16 2000-09-26 アフィメトリックス，インコーポレイテッド 標識材料を検出するシステムおよび方法
US6335170B1 (en) * 1999-02-22 2002-01-01 Torben F. Orntoft Gene expression in bladder tumors
WO2002048310A2 (fr) * 2000-12-15 2002-06-20 Genetics Institute, Llc Procedes et compositions permettant de diagnostiquer et de traiter la polyarthrite rhumatoide

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2004016809A1 *

Also Published As

Publication number Publication date
AU2003285285A1 (en) 2004-03-03
WO2004016809A1 (fr) 2004-02-26
DE10234524A1 (de) 2004-02-12
US20060216707A1 (en) 2006-09-28

Similar Documents

Publication Publication Date Title
DE69829402T2 (de) Expressionsprofile in adulten und fötalen organen
EP2004846B1 (fr) Profils d'expression destines a la prevision d'etats septiques
DE69918072T2 (de) P53-regulierte gene
DE10296990B4 (de) Verwendung eines Biochips zur Diagnose von Sepsis und sepsisähnlichem Syndrom
DE69535428T2 (de) Verfahren zum Auffinden von differentiel exprimierte Gene
DE112005002742B4 (de) Verbindungen und Methoden zur Behandlung, Diagnose und Prognose bei Pankreaserkrankungen
EP1721002B1 (fr) Methode pour identifier une sepsie
EP2366799A2 (fr) Procédé de reconnaissance in vitro de septicémie aigüe
EP1523575A1 (fr) Jeu ordonne d'acides nucleiques constitue de genes selectifs de monocytes-macrophages
DE10155600B4 (de) Nukleinsäure-Array
EP1863928B1 (fr) Utilisation de classificateurs d'activite genetique pour la classification in vitro de profils d'expression genetique de patients presentant une defaillance multiorganique infectieuse ou non-infectieuse
DE102004049897B4 (de) Verfahren zur Unterscheidung zwischen nichtinfektiösen und infektiösen Ursachen eines Multiorganversagens
US20030157548A1 (en) Method for diagnosing schizophrenia using objective indices
DE60117555T2 (de) Bewertungssystem für die vorhersage von krebsrezidiven
WO2005106020A1 (fr) Procede pour predire l'evolution individuelle d'une maladie en cas de sepsis
DE102010043541B4 (de) Verfahren und Mittel zur Vorhersage der Überlebensdauer beim Pankreaskarzinom durch Analyse von Biomarkern
DE10315031B4 (de) Verfahren zur Erkennung von Sepsis und/oder sepsisähnlichen Zuständen
DE10336511A1 (de) Verfahren zur Erkennung von schwerer Sepsis
DE102020111423B4 (de) MYH11/NDE1 Region als epigenetischer Marker für die Identifizierung von Endothel-Vorläuferzellen (EPCs)
WO2000071747A2 (fr) Systeme de detection aux fins de separation des constituants d'un prelevement, sa production et son utilisation
DE10340395A1 (de) Verfahren zur Erkennung akuter generalisierter entzündlicher Zustände (SIRS)
EP2914746A2 (fr) Procede de determination du vieillissement independamment du sexe
WO2004005542A2 (fr) Procede d'identification de genes de la peau regules specifiquement a une infection
WO2002097119A2 (fr) Utilisation de la mise en evidence de l'expression de variants d'epissage du gene 21 pour le diagnostic et le traitement de maladies tumorales
WO2009015799A2 (fr) Détection de la résistance au platine

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20050119

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK

DAX Request for extension of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20081202